Color Code
Brown

Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study

768
world
Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study
Illinois, Mississippi, Pennsylvania and Washington D.C., USA
United States of America
To learn lessons about how best to incorporate the delivery of daily oral pre-exposure prophylaxis (PrEP) into the services provided by health centers serving sexually active adults at high risk of acquiring HIV infection. The pilot study will initiate data collection at federally-qualified health centers (FQHCs) or look-alikes in four U.S. cities.
Gilead Sciences, Inc.
CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; Central Care Community Health Center; Strawberry Mansion Health Center; Access Community Health Network – Grand Boulevard Clinic; Newark Community Health Centers, Inc.; University of Colorado

Multistate Fungal Meningitis Outbreak Management

742
environmental health
Multistate Fungal Meningitis Outbreak Management
United States of America
To respond to an unprecedented outbreak of central nervous system, joint and osseous mold infections that have been observed, beginning in August of 2012, among hundreds of patients who received contaminated methylprednisolone injections. This project will collect long-term follow-up data on diagnosis and appropriate treatment of fungal meningitis and other fungal infections associated with this outbreak in order to fully understand and track the burden of these infections.
Springer Science+Business Media LLC
CDC’s National Center for Emerging and Infectious Zoonotic Diseases

Rift Valley Fever Virus Vaccination Development

707
Rift Valley
Rift Valley Fever Virus Vaccination Development
United States of America
To assist in the development of novel vaccines and comprehensive strategies for the prevention of Rift Valley Fever virus in both livestock and humans using recombinant proteins and 96-well ELISA or Luminex platforms to detect anti-NP, anti-NSs or anti-NSm antibodies.
Texas A&M University
CDC’s National Center for Emerging and Zoonotic Infectious Diseases

Global Burden of Foodborne Norovirus

684
food
Global Burden of Foodborne Norovirus
United States of America
To estimate incidence rates of gastroenteritis due to norovirus by age and country/WHO region, taking; to describe and quantify the available data on health effects resulting from these infections; to estimate the proportion of norovirus that is foodborne; and to provide a critical appraisal of data gaps.
World Health Organization
CDC's National Center for Immunization and Respiratory Diseases

Point-of-Care Diagnostics for Norovirus

674
Norovirus
Point-of-Care Diagnostics for Norovirus
United States of America
To help CDC collaborate in a larger norovirus study by developing glycan-based assays to evaluate a panel of different synthetic glycans as well as norovirus stool strains.
Georgia State University (National Institutes of Health)
CDC's National Center for Immunization and Respiratory Diseases

Controlling Viral Foodborne Disease

635
food
Controlling Viral Foodborne Disease
United States of America
To help CDC collaborate with the U.S. Department of Agriculture and the National Institute of Food and Agriculture to create an integrated, multi-disciplinary approach to developing improved tools, skills and capacity to study foodborne viruses. Outcomes of the partnership will be used to systematically identify risk factors and develop risk management strategies to reduce contamination in pre- and post-harvest environments.
North Carolina State University; United States Department of Agriculture
CDC's National Center for Immunization and Respiratory Diseases

Synthesis of XMRV Peptides

569
lab
Synthesis of XMRV Peptides
United States of America
To develop a mass spectrometry method that can be used to identify and quantify a novel protein produced by the prostate-cancer-associated retrovirus XMRV in patient samples.
Edinburgh Napier University; Emory University School of Medicine; Lypro Biosciences, Inc.; The Children’s Hospital of Philadelphia; University of Maryland Baltimore (National Institutes of Health); University of Louisville; Global Blood Therapeutics
CDC's National Center for Emerging and Zoonotic Infections

Viral Hepatitis Action Coalition

The Viral Hepatitis Action Coalition is a public-private partnership developed by the CDC Foundation to help the Centers for Disease Control and Prevention (CDC) make meaningful advances in the prevention, screening, and treatment of viral hepatitis.

A report on hepatitis and liver cancer issued by The National Academies of Sciences, Engineering and Medicine (formerly the Institute of Medicine (IoM)) in 2010 highlighted an overall lack of knowledge about the extent and seriousness of viral hepatitis in the United States. The report specifically called on CDC to work with public and private partners to:

  • increase data collection on hepatitis B and hepatitis C to provide a better overall understanding of how many people are infected, how they became infected, if and when they got tested and treated, and the outcomes of their treatment; and
  • educate populations at-risk, healthcare providers, and the general public about hepatitis to promote vaccination and prevention strategies and encourage screening and testing

Through the Viral Hepatitis Action Coalition, CDC was able to respond to the urgent calls to action outlined in the 2010 report. Members of the Coalition helped support crucial CDC-led research and programs and amplified CDC’s messages to the public to increase overall awareness of viral hepatitis. From 2010 to 2017, the Coalition successfully facilitated and supported the convening of several meetings, summits, and forums for stakeholders to discuss topics including:

  • CDC’s priorities toward building state and local capacity to prevent viral hepatitis
  • Critical interventions needed to improve the continuum of HCV testing, care, and treatment in the United States
  • U.S. domestic and global topics on prevention and control of viral hepatitis 
  • Stopping the hepatitis C epidemic among young persons who inject drugs

VHACThe final effort that the Coalition lead was convening a public meeting to discuss the National Academies of Science, Engineering, and Medicine expert committee's 2017 report outlining a strategy to eliminate hepatitis B and C as public health problems in the United States. This Hepatitis B and C Elimination Summit cumulated and demonstrated the Coalition’s success in providing a framework to support the initiation of research and program evaluation through partnerships that promote information sharing, stakeholder collaboration, and shared commitment to public health initiatives.

"The Viral Hepatitis Action Coalition has given us capacity that we did not have previously to launch a variety of new projects that our division believes are critically important to our success in preventing disease and deaths from viral hepatitis," says John Ward, Director of CDC’s Division of Viral Hepatitis. 

To learn more about the legacy of the Viral Hepatitis Action Coalition, please contact CDC’s Division of Viral Hepatitis. View a report on the achievements of the Viral Hepatitis Action Coalition.
 

About CDC's Division of Viral Hepatitis

labIn collaboration with domestic and global partners, CDC's Division of Viral Hepatitis (DVH) provides the scientific and programmatic foundation and leadership for the prevention and control of hepatitis virus. DVH conducts research, surveillance, education and training, and evaluation to facilitate policy and design interventions to address the most common forms of viral hepatitis in the United States: hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV). These unrelated viruses are transmitted through different routes and require specific prevention strategies. CDC also conducts surveillance and investigation of other forms of viral hepatitis, particularly those common in other parts of the world, and serves as a WHO Collaborating Center for Reference and Research on Viral Hepatitis.

Learn more: www.cdc.gov/hepatitis

511
Viral Hepatitis Action Coalition
Viral Hepatitis Action Coalition
United States of America
To provide an overall framework for organizations concerned with viral hepatitis to support high priority research, education and program evaluation projects initiated by CDC's Division of Viral Hepatitis.
Abbott Laboratories; AbbVie; Bristol-Myers Squibb; Gilead Sciences, Inc.; Janssen Therapeutics; Merck Sharp & Dohme; OraSure Technologies; Quest Diagnostics; Siemens Healthcare Diagnostics; Alere North American, Inc.; Bayer Corporation; Boehringer Ingelheim; Genentech; Gen-Prob, Inc.; GlaxoSmithKline; Kadmon Pharmaceuticals; Onyx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc.
CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention; Association of State and Territorial Health Officials (ASTHO); National Viral Hepatitis Roundtable

Treatment of TB with Priftin (rifapentine)

393
TB - CDC image
Treatment of TB with Priftin (rifapentine)
Texas, Colorado, California, Ohio, Washington DC, North Carolina, Tennessee, USA
United States of America
To continue the research and development of the drug Priftin® (rifapentine) and to investigate its role in the treatment of active tuberculosis (TB) disease and latent TB infection.
Sanofi Foundation for North America
CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention

Norovirus In-Vitro Time-Kill Evaluation

401
Norovirus
Norovirus In-Vitro Time-Kill Evaluation
United States of America
To evaluate commercial sanitizing products for their virucidal effectiveness against murine norovirus.
Applied Biocode; Cepheid; Luminex Corporation; Nanosphere, Inc.; R-Biopharm, Inc.
Previous Partners: Arch Chemicals, Inc.; Byotrol; Clemson University; GOJO Industries, Inc.; Holland America Line; IISES, LLC; International Atomic Energy Agency; LigoCyte Pharmaceuticals; Molnlycke Health Care, LLC; Oxoid Ltd.; Pathcon Laboratories; Proctor & Gamble Company; Radco Chemical Solution; Remel, Inc.; Takeda Pharmaceuticals; University of Queensland; Therapeutic Goods; University of North Carolina
CDC's National Center for Immunization and Respiratory Diseases
Subscribe to Infectious Disease